Key result
Continuous intravenous administration of landiolol after off-pump coronary artery bypass significantly reduced the incidence of atrial fibrillation during ICU stay (2.6% vs 20%).
Why the study?
Does intravenous landiolol reduce the incidence of atrial fibrillation in patients after off-pump coronary artery bypass?
Cohort (n=59)
Does intravenous landiolol reduce the incidence of atrial fibrillation in patients after off-pump coronary artery bypass?
Continuous low-dose intravenous landiolol significantly reduces the incidence of postoperative atrial fibrillation in patients undergoing off-pump coronary artery bypass.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for landiolol after off-pump CABG; randomized trials needed before practice change.
OBJECTIVES: many studies have shown that oral beta blockers reduce the incidence of atrial fibrillation after coronary artery bypass. The goal of this study was to determine whether landiolol, an intravenous beta blocker, reduces the incidence of atrial fibrillation after off-pump coronary artery bypass. METHODS: 39 consecutive patients were given landiolol after coronary artery bypass, and 20 who were not given landiolol served as a control group. Landiolol was intravenously administered at 1 µg.kg(-1).min(-1) in the intensive care unit. RESULTS: the mean dose of landiolol was 2.3 ± 1.2 1 µg.kg(-1).min(-1). The incidence of atrial fibrillation during intensive care unit stay was significantly lower in the landiolol group compared to the control group: 2.6% (1/39) vs. 20% (4/20). Heart rate after landiolol administration was significantly lower than that before administration, whereas landiolol had no effect on blood pressure. C-reactive protein and creatine kinase levels 7 days after surgery were significantly lower in the landiolol group. CONCLUSION: continuous administration of landiolol at a low dose after off-pump coronary artery bypass reduced the incidence of atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Maisawa et al. (2013) conducted a cohort in Off-pump coronary artery bypass (n=59). Landiolol vs. No landiolol was evaluated on Incidence of atrial fibrillation during intensive care unit stay. Continuous intravenous administration of landiolol after off-pump coronary artery bypass significantly reduced the incidence of atrial fibrillation during ICU stay (2.6% vs 20%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: